Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model

Terryl J. Mast, Mark A. Cukierski, Heinz Nau, Andrew G Hendrickx

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The anticonvulsant, valproic acid (VPA) is a suspected human teratogen. This study, employing the rhesus monkey as an animal model, demonstrates that VPA has a significant teratogenic potential in the monkey. Timed pregnant monkeys were exposed orally to VPA at approx. 1X, 10X, and 30X (20, 200, and 600 mg/kg/day, respectively) the human therapeutic dose, daily, during organogenesis (gestation days 21-50). All fetuses of mothers exposed to greater than 1X exhibited some form of embryotoxicity. The highest dose, 30X, was 110% embryolethal, while offspring of the 10X dose group exhibited craniofacial and skeletal defects, and low body weights. Maternal pharmacokinetic parameters and plasma metabolites were determined for VPA on the first and last day of dosing for the 10X dose group. Comparison on the kinetic and metabolite data with that obtained for man indicates that the rhesus monkey is a good model for predicting the teratogenic potential of VPA in the human.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalToxicology
Volume39
Issue number2
DOIs
StatePublished - 1986

Fingerprint

Valproic Acid
Anticonvulsants
Primates
Metabolites
Macaca mulatta
Haplorhini
Mothers
Teratogens
Pharmacokinetics
Organogenesis
Animals
Fetus
Animal Models
Body Weight
Plasmas
Pregnancy
Defects
Kinetics

Keywords

  • 2-Propylpentanoic acid
  • Pharmacokinetics
  • Rhesus monkey
  • Teratology
  • Valporic acid

ASJC Scopus subject areas

  • Toxicology

Cite this

Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. / Mast, Terryl J.; Cukierski, Mark A.; Nau, Heinz; Hendrickx, Andrew G.

In: Toxicology, Vol. 39, No. 2, 1986, p. 111-119.

Research output: Contribution to journalArticle

Mast, Terryl J. ; Cukierski, Mark A. ; Nau, Heinz ; Hendrickx, Andrew G. / Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. In: Toxicology. 1986 ; Vol. 39, No. 2. pp. 111-119.
@article{adffa4f6e8e242f99bea6f732bc068fa,
title = "Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model",
abstract = "The anticonvulsant, valproic acid (VPA) is a suspected human teratogen. This study, employing the rhesus monkey as an animal model, demonstrates that VPA has a significant teratogenic potential in the monkey. Timed pregnant monkeys were exposed orally to VPA at approx. 1X, 10X, and 30X (20, 200, and 600 mg/kg/day, respectively) the human therapeutic dose, daily, during organogenesis (gestation days 21-50). All fetuses of mothers exposed to greater than 1X exhibited some form of embryotoxicity. The highest dose, 30X, was 110{\%} embryolethal, while offspring of the 10X dose group exhibited craniofacial and skeletal defects, and low body weights. Maternal pharmacokinetic parameters and plasma metabolites were determined for VPA on the first and last day of dosing for the 10X dose group. Comparison on the kinetic and metabolite data with that obtained for man indicates that the rhesus monkey is a good model for predicting the teratogenic potential of VPA in the human.",
keywords = "2-Propylpentanoic acid, Pharmacokinetics, Rhesus monkey, Teratology, Valporic acid",
author = "Mast, {Terryl J.} and Cukierski, {Mark A.} and Heinz Nau and Hendrickx, {Andrew G}",
year = "1986",
doi = "10.1016/0300-483X(86)90129-0",
language = "English (US)",
volume = "39",
pages = "111--119",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model

AU - Mast, Terryl J.

AU - Cukierski, Mark A.

AU - Nau, Heinz

AU - Hendrickx, Andrew G

PY - 1986

Y1 - 1986

N2 - The anticonvulsant, valproic acid (VPA) is a suspected human teratogen. This study, employing the rhesus monkey as an animal model, demonstrates that VPA has a significant teratogenic potential in the monkey. Timed pregnant monkeys were exposed orally to VPA at approx. 1X, 10X, and 30X (20, 200, and 600 mg/kg/day, respectively) the human therapeutic dose, daily, during organogenesis (gestation days 21-50). All fetuses of mothers exposed to greater than 1X exhibited some form of embryotoxicity. The highest dose, 30X, was 110% embryolethal, while offspring of the 10X dose group exhibited craniofacial and skeletal defects, and low body weights. Maternal pharmacokinetic parameters and plasma metabolites were determined for VPA on the first and last day of dosing for the 10X dose group. Comparison on the kinetic and metabolite data with that obtained for man indicates that the rhesus monkey is a good model for predicting the teratogenic potential of VPA in the human.

AB - The anticonvulsant, valproic acid (VPA) is a suspected human teratogen. This study, employing the rhesus monkey as an animal model, demonstrates that VPA has a significant teratogenic potential in the monkey. Timed pregnant monkeys were exposed orally to VPA at approx. 1X, 10X, and 30X (20, 200, and 600 mg/kg/day, respectively) the human therapeutic dose, daily, during organogenesis (gestation days 21-50). All fetuses of mothers exposed to greater than 1X exhibited some form of embryotoxicity. The highest dose, 30X, was 110% embryolethal, while offspring of the 10X dose group exhibited craniofacial and skeletal defects, and low body weights. Maternal pharmacokinetic parameters and plasma metabolites were determined for VPA on the first and last day of dosing for the 10X dose group. Comparison on the kinetic and metabolite data with that obtained for man indicates that the rhesus monkey is a good model for predicting the teratogenic potential of VPA in the human.

KW - 2-Propylpentanoic acid

KW - Pharmacokinetics

KW - Rhesus monkey

KW - Teratology

KW - Valporic acid

UR - http://www.scopus.com/inward/record.url?scp=0022646612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022646612&partnerID=8YFLogxK

U2 - 10.1016/0300-483X(86)90129-0

DO - 10.1016/0300-483X(86)90129-0

M3 - Article

C2 - 3085290

AN - SCOPUS:0022646612

VL - 39

SP - 111

EP - 119

JO - Toxicology

JF - Toxicology

SN - 0300-483X

IS - 2

ER -